Index [ ] 1631 Index a a emitters 422 A-DOXO-HYD 777, 778 A121 human ovarian tumor xenograft 1348 a2-macroglobulin

  • View
    0

  • Download
    0

Embed Size (px)

Text of Index [ ] 1631 Index a a emitters 422 A-DOXO-HYD 777, 778 A121 human ovarian tumor xenograft 1348...

  • 1631

    Index

    a a emitters 422 A-DOXO-HYD 777, 778 A121 human ovarian tumor xenograft 1348 a2-macroglobulin 65 AAG (α1-acid glycoprotein) 1341 AAV (adeno-associated virus) 1426, 1433 AB.Fab fragments 109 ABC (ATP-binding cassette) transporters

    1493, 1494 – inhibition, 1497 ABD (albumin-binding domain) 107 aberrant branching 693 ablation 971 – radiofrequency tumor 971 – thermal 898 ablative therapy – local 1521 absorption, distribution, metabolism, and

    excretion (ADME) 1173, 1174 AcBut hydrazone linker 112 accessible vascular targets – mapping 430 accumulation 1263 – differential 1263 – maytansinoid metabolites 391 – nanocarriers 991 ACE (angiotensin II-converting enzyme)

    79 acetals – trimethoxybenzylidene 1112 acetamide functionality 73 α1-acid glycoprotein (AAG) 1341 acid-activated PEG–drug conjugates 651 acid-cleavable linkages 1103 acid-labile hydrazone linker 103, 261 acid-sensitive conjugates 772, 1536 acid-sensitive linkages 5, 738

    acid-sensitive linkers 24 acid-treated SWNTs 1175 acidic intracellular compartments 92 acidification – progressive 991 acidity – extracellular 1100 acidosis 53, 55 acrylamide – PEG 19 acrylic copolymers 1072 activated carboxy groups 1312 activation 989 – AMCs 385, 389 – biocatalytic 564 – endothelial cells 591 – external 1001 – heat 1001 – innate enzymes 1000 – lysosomal 387 – magnetic field 1006 – oxidative 569 – pH-dependent 569 – photochemical 572 – protease-dependent 1203 – reductive 566 – tumor-intrinsic stimuli 994 – tumor-specific 564 – ultrasound 1005 – UV/IR 1003 active targeting 1057 – CPPs 1205 – platinum complexes 1612 – SPIO particles 232 activity – SAR 19 actual delivery – uniformity 989

    Drug Delivery in Oncology: From Basic Research to Cancer Therapy, First Edition. Edited by Felix Kratz, Peter Senter, and Henning Steinhagen.  2012 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2012 by Wiley-VCH Verlag GmbH & Co. KGaA.

  • 1632 Index

    acute lymphoblastic leukemia (ALL) 3 acute lymphocytic leukemia (ALL) 105 acute myeloid leukemia (AML) 96 acyclization-based SIL 556 acyl hydrazone-based conjugates 1299 acyl tail dynamics – lipid 999 adaptors – chemical 573 ADC (apparent diffusion coefficient) 35, 54 ADCC (antibody-dependent cellular

    cytotoxicity) 47, 292 ADCs 108 addition – Michael-type 559 adducts – platinum–DNA 1035 adeno-associated virus (AAV) 1426, 1433 adenocarcinomas 1457 adenovirus serotype 5 (Ad5) 1500 adenoviruses 1392, 1400 – oncolytic 1431 ADEPT (antibody-directed enzyme prodrug

    therapy) 6, 16, 17, 34, 951 – two-phase clinical trials 25 adhesion molecule – epithelial cell 960 adjuvant bisphosphate therapy 807 administration 951 – antibody-targeted liposomal drugs 951 – combination chemotherapy 1022 adrenocortical tumors – imaging 279 AEC 18 aerosolized liposomal paclitaxel 970 AEZS-108 1235 affinity – antibodies 21 AFM13 469 agents 1013 – alkylating 34 – amphipathic 1041 – anti-MDR 1026 – antiangiogenic 599 – anticancer 45, 747, 763 – antineoplastic 276 – bifunctional chelating 92 – chain transfer 266 – chemically incompatible 1026 – complexation 253 – contrast 276, 1063 – conventional anticancer 7 – DNA-damaging 94 – hydrophobic 1040

    – intravenously injected 328 – microtubule-stabilizing 24 – molecularly targeted 808 – NO-releasing 78 – radioimmunoscintigraphy 417 – radionuclide delivery 423 – reactive 1033 – surface stabilizing 1041 – therapeutic 443 aggregation – liposomes 1005 aglycone functionality – enediyne 95 AGM (aminogluthetimine) 820 AIDS-related Kaposi’s sarcoma 919, 922 AIF (apoptosis-inducing factor) 1453, 1470 alanine transaminase 1542 albondin 792 albumin 747, 1099 – bovine serum 566, 1123 – carrier 786 – cationized 1501 – CBSA 1138, 1504 – cross-linked matrix 1136 – drug conjugates 772 – Evans blue– 73 – human serum 750, 862, 1133, 1323 – lactosaminated 1532 – microspheres 761 – mouse serum 90 – nab technologies 895, 1136 – nanoparticles 895, 1133, 1150 – serum 85 – synthetic approaches 759 – transcytosis 1134 – zzz 763 albumin-based nanoparticles – clinical studies 1152 albumin-binding domain (ABD) 107 albumin-conjugated PEGylated nanoparticles – cationic 1149 alemtuzumab 292 alendronate (ALN) 823, 825 alginate–drug conjugates 730 aliphatic anchors 1043 aliphatic systems – releasable PEG linkers 649 alkylating agents 34 alkylating lysines 298 alkylation – reductive 633 alkylator – DNA 1336 ALL (acute lymphoblastic leukemia) 3

  • Index 1633

    ALL (acute lymphocytic leukemia) 105, 107 alternative scaffolds 431 amides 1219 – amide/amino-derived linkages 646 – aromatic 1340 – spontaneous ring-closure 557 amino acids 12 – ω-amino fatty acids 1249 – metabolism 37 – transport imaging 257 – zwitterionic residue 77 amino groups – lysine 1578 aminoacyl-tRNAs 1459 aminogluthetimine (AGM) 820 aminolysis 258 aminopeptidase P2 (APP2) 342 aminopolysaccharides 717 amiRNA 1421 AML (acute myeloid leukemia) 400 amlodipine 1026 ammonia ligands 1607 amphipathic drugs 909 amphipathic peptides – Pep-3 1197 amphipathic surface stabilizing agents

    1041 amphiphilic block copolymers 1103 amphiphilic polymers 627 – self-assembly 1078 AN-152 1235 – chromophore-labeled 1227 – fluorophore-labeled 1227 – structure 1224 AN-162 1239 AN-238 1238 analysis 1283 – analytical completeness 337, 338 – biodistribution 343 – retro-synthetic 1288 – western 339 anastomosis – vessel 591 anatomic information – coregistration 282 anatomy of BBB 1490 anchors – aliphatic 1043 anemia 52 angiogenesis 36 – basic principles 34 – cytotoxic somatostatin analogs 1237 – imaging 260 – liver cancer 1551

    – schematic representation 592 – tumors 13, 65, 591 angiogenic cascade 34 angiogenic factors 1419 angiogenic markers 1443 – dual targeting 616 – potential 596 angiogenic proteins 35 angiogenin 1453 angiographic arterial infusion 71 angiotensin II 75 angiotensin II-converting enzyme (ACE) 79 angiotensin-converting proteins 341 animal studies – albumin-based nanoparticles 1139 anionic phospholipids 1373 AnnA1 knockout mice 65 Annexin-A1 (AnnA1) 344 antagonistic analogs – GHRH 1249 antagonists 1219 – bombesin/GRP 1219 – GHRH 1247 Antennapedia protein – Drosophila 1189 anthracycline-based regimen 12 anthracyclines 929, 933 anthrax toxin 1450, 1465 anti-ASNase antibodies 631 anti-CEA monoclonal antibody – murine 25 anti-CEA scFv–Fc variants 99 anti-HER2 liposomes – Fab¢ fragments 958 anti-HER2 mAb 957 anti-MDR agent – amlodipine 1026 anti-mouse antibody – human 111 anti-murine antibody – human 455 anti-PEG Ig-mAb 79 antiangiogenesis 617 antiangiogenic agents 599 antiangiogenic approved therapies 593 antiapoptotic proteins 1228 antibiotics 1519 – benzoquinone ansamycin 605 – chromophore dienediyne 1543 antibodies 5 – ADCs 110 – ADEPT 19 – affinity 21, 100 – anti-ASNase 631

  • 1634 Index

    antibodies (contd.)

    – anti-PEG Ig-mAb 79 – antibody–toxin conjugates 14 – antienzyme 22 – binding 7 – BsAbs 430, 483 – caveolae-dependent trafficking 329 – chimeric 292, 444 – clinical trials of ADCs 14 – conjugated 449 – delivery agents 423 – DiBi mini- 459 – dimeric domain 457 – effector functions 291, 293 – empowered 49 – engineered fragments 424, 425 – fluorescently labeled 331 – HAMA 455 – hetero-oligomeric 455 – human anti-mouse 111 – humanized 414, 444 – indirect photosensitizer-linker-mAb

    conjugates 1580 – intact 424, 425 – loaded 111 – marketed therapeutic 445 – monoclonal 24 – neutralizing 1459 – nucleosome-specific 961 – photosensitizer targeting 1575 – radiolabeled 412 – radionuclide delivery 411 – TandAb 469 – targeting ligands 1381 – targeting moieties 1205 – therapeutic agents 443 – ‘‘two-in-one’’ 453 antibody fragments – PEGylated 634 antibody-based macromolecular systems 37 antibody-dependent binding 1203 antibody-dependent cellular cytotoxicity

    (ADCC) 38, 432 antibody-directed enzyme prodrug therapy

    (ADEPT) 17 antibody-mediated long-circulating liposome

    955 antibody-modified liposomes 962 antibody-targeted chemotherapy 94 antibody-targeted liposomal drugs 968 antibody-targeted liposomes 954, 956 antibody–drug conjugates (ADCs) 450 – auristatin-based 305, 309 – calicheamicin-based 94, 253

    – cancer therapy 295 – cytotoxic 72 – linker technologies 69 – most successful 86 – pharmacokinetics 300 antibody–maytansinoid conjugates (AMCs)

    375 – activation 385 – clinical trials 384 – structure 378 anticancer agents 1013 – carriers 747 – complexation 253 – extravasation 45 – LDL 763 – serum albumin 763 – structure 7 – transferrin 763 anticancer combination therapy – fixed ratio 1014 anticancer drugs – categories 5 anticancer formulations – liposomal 1007 anticancer liposomal drugs 954 anticancer platinum complexes 1605 antienzyme antibodies 22 antiestrogens 1612 antifolates 4 antigen 1163 – carcinoembryonic 19, 99, 425, 1167 – CD19 958 – hematopoietic 95 – prostate-specific 562 – PSMA 295 – target 295 antigen presentation – FcRn 93 antigen-binding domain 86, 1447 antigen-mediated processing 385 – efficiency 387 antimetabolites 34 antineoplastic activity – inherent 1195 antineoplastic agents 275 antineoplastic cargo 1192 antineoplastic platinum complexes 853 antinuclear autoantibodies (AnA) 961 – nucleosome interachtion 964 antiproliferative effect 952 – Bac-ELP-p21 688 – Pen-ELP-H1 686 antiretroviral therapy – HAART 921

  • Index 1635

    antisense oligonucleotides 543 antisense strand phosphorylation